Þorkell Andrésson

This study develops SMYD3 proteolysis targeting chimeras (PROTACs) for HPV-negative head and neck squamous cell carcinoma, showing effective SMYD3 degradation and reduced oncogenic activity.

This study identifies phosphorylation as a mechanism protecting oncogenic RAS from LZTR1-mediated degradation, with implications for targeting RAS stability in hematologic cancers.

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

The paper uses phosphoproteomic data and KMEA to identify tumor-specific kinase activity in GEP-NETs, revealing potential therapeutic targets.

This study identifies hepatobiliary progenitor-like reprogramming in liver metastases, driven by TGF-β and hypoxia, and shows its association with poor survival.

This paper identifies RRP1B as a stress-responsive regulator of RNA processing and splicing in breast cancer, showing its role in splicing programs and tumor aggressiveness.

This study shows that IFITM1 and IFITM3 work together to block virus entry in endolysosomes, with IFITM3 promoting IFITM1 localization to these compartments.

The paper identifies non-coding variants in CDKN2B that disrupt CTCF binding, reduce CDKN2A expression, and increase melanoma risk in families.

This paper evaluates the potency and selectivity of MYST KAT inhibitors using chemoproteomic profiling and identifies new complex members, highlighting dose-dependent inhibition patterns and potential therapeutic applications.

This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

The paper presents an isoform-level lung cell atlas using single-cell long-read RNA-sequencing, revealing genetic effects on isoform regulation that improve cell-type classification and identify novel variants associated with lung cancer risk.

This study shows that targeting PDPK1 and BRAF V600E together is a potent therapy for anaplastic thyroid cancer, leading to tumor regression through synergistic signaling inhibition and apoptosis.

The paper identifies functional variants and VNTRs at the 5p15.33 locus using fine-mapping, MPRA, and CRISPRi screens, revealing their role in cancer susceptibility through antagonistic pleiotropy.

This paper compares two 3D culture models for breast cancer cells, finding that the EmC model better mimics lung metastasis by altering metabolism and gene expression.

This study identifies RAPGEF1 as a gene modulating melanoma and nevi risk through RAS activation, using fine-mapping, expression data, and functional assays.

This paper develops a scalable method to generate pure CD103+ cDC1 from mouse bone marrow cultures, achieving high purity and yield for immunological studies.

The paper introduces CRASP-Seq, a method to identify gene regulators of alternative splicing, and finds ZNF207 regulates LMNA splicing in progeria by interacting with U1 snRNP.

The paper develops a perfusion circuit system to preserve tumor microenvironments in 3D patient-derived tumor models for up to 48 hours, enabling complex drug interrogations.

This study shows that tRNA acetylation regulates stress signaling in mammals by affecting ribosome function and interacting with the Gcn2 kinase.

This study identifies acetylation of the Integrator complex as a key determinant of gene-specific transcriptional bursting patterns through high-throughput imaging screens.

This paper develops a 3D self-assembly system to engineer tumor stroma-like structures using decellularized ECM and cancer cells, showing effects on malignancy and metabolism.

The paper develops activity-based probes to selectively detect USP18 activity and screen for inhibitors, enabling analysis of USP18's role in disease states.

The paper fine-maps a PDAC GWAS signal at chr1p36.33 and identifies KLHL17 as a target gene regulated by JunB/D, with potential implications for inflammation and PDAC risk.

The paper identifies MPC1 as a key driver of PARP inhibitor resistance in NSCLC lung cancer through a metabolism-focused CRISPR screen.

This study shows that NAT10 loss reduces lung metastasis by disrupting enhancer organization through p300 mislocalization and altering gene transcription related to metastasis.

This study investigates how fumarate accumulation affects RNA methylation by targeting specific 2OGDD enzymes in HLRCC cell lines, revealing differential impacts on m6A, m1A, and f5C demethylases.

The paper identifies a chemical scaffold targeting hRpn13, revealing a DEUBAD-lacking isoform upregulated in multiple myeloma and demonstrating its potential as a therapeutic target.

The paper identifies a novel NRAS variant in a melanoma-prone family and shows it impairs MAPK/AKT signaling while enhancing PI3K signaling.

The paper identifies a novel proteasome-binding site in E6AP mediated by hRpn10, showing E6AP's unique interaction with the proteasome for substrate ubiquitination.